Yvonne M. Saenger
<p>Dr. Yvonne Saenger is an expert in cancer immunotherapy with a focus on melanoma and gastro-intestinal tumors</p>
<p>The Saenger laboratory researches immune biomarkers for melanoma recurrence to stratify patients for adjuvant immunotherapy. Digital pathology and artificial intelligence methods are used.</p>
<p>A second area of focus is analysis of the tumor immune micro-environment in liver cancer, particularly on studying human specimens and organoids to define the role of immune cell populations and complement in tumor progression.</p>
Immunotherapy for hepatocellular cancer
Immunotherapy biomarkers for solid tumors
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Gartrell-Corrado RD, Chen A, Rizk EM , Marks DK, Bogardus M, Hart TD, Silverman AM, Bayan CA, Finkel G, Barker L , Komatsubara KM, Carvajal RD, Horst BA, Chang R, Monod A , Rabadán R, <strong>Saenger Y</strong>, “Linking transcriptomic and imaging data </span><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma,” <em>Cancer Research.</em> 2020 Mar 1;80(5):1078-1087. PMID: 31948941</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Kulkarni PM, Robinson EJ, Pradhan JS, Gartrell-Corrado RD, Rohr B, Kluger HM, Wong PF, Acs B, Rizk EM, Yanc C, Mondal M, Moore M, Phelps R, Hoorst BA, Ferringer T, Rimm DL, Wang J, <strong>Saenger Y</strong>, “Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death,” <em>Clinical Cancer Research</em></span><span style="font-size: 14pt; font-family: Calibri, sans-serif;">. 2019 Oct 21. <em>Clinical Cancer Research</em>.1495.2019. PMID: 31636101</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;"> </span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gerard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst B, <strong>Saenger YM, “</strong></span><strong><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma,”</span></strong> <strong><em><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">Clinical Cancer Research</span></em></strong><strong><em><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">, </span></em></strong><strong><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">2019 Jan 15</span></strong> <span style="font-size: 14pt; font-family: Calibri, sans-serif;">PMID: 30647081</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;"> </span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Zhao J, Chen AX, Gartrell RD, Silverman A, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Goetz M, Yagamuchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yun J, Canoll P, Bruce JN, <strong>Saenger YM</strong>, Sims P, Iwamoto FB, Sonabend AM, Rabadan, R. “Longitudinal genomic study of response to anti-PD-1 immunotherapy in Glioblastoma Multiforme<em>,” Nature Medicine 2019 </em>Mar 25(3):462-469 PMID: 30742119</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;"> </span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, <strong>Saenger YM, “</strong>Quantitative Analysis of Immune Infiltrates in Primary Melanoma,”<span class="jrnl"> <em>Cancer Immunol Res</em></span><em>.</em> 2018 <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Apr;6(4):481-493</span> PMID: 29467127</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;"> </span></span></p>
<p class="desc" style="margin: 0in 2pt 0in 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE, Perni S, Weisberg SP, Rizk EM, Wang S, Oh EJ, Guo XV, Chiuzan C, Manji GA, Bates SE, Chabot J, Schrope B, Kluger M, Emond J, Rabadán R, Farber D, Remotti HE, Horowitz </span></span><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">DP, <strong>Saenger YM. </strong></span></span><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma, <span class="docsum-journal-citation">Oncoimmunology. 2022 May 5. PMID: </span><span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">35558160</span></span></p>
<p> </p>
<p> </p>